Brad Rovin Archives

Tag: Brad Rovin

How Are the New Lupus Nephritis Guidelines Impacting Treatment?

Recognized as National Kidney Month, March is the ideal time to learn more about the 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Recently issued, the guidelines are designed to provide healthcare providers with up-to-date guidance on the care and treatment of adults and children with lupus […] Read More

Independent Panel Gives High Marks to New Lupus Nephritis Therapies, Policies Reflect LRA Feedback

April 20, 2021 At a public meeting in March led by the Institute for Clinical and Economic Review (ICER), an independent panel voted unanimously that both belimumab (Benlysta) and voclosporin (Lupkynis), newly approved to treat lupus nephritis, provide a health benefit over standard therapy alone. ICER’s policy recommendations for the use of these two medications […] Read More

Join LRA March 11 to Learn What’s New in Lupus Nephritis

What’s New in Lupus Nephritis? A Research & Treatment Update A Learn from Lupus Webcast Lupus nephritis is a common and dangerous complication of lupus marked by inflammation that can lead to damage and possible failure of the kidney. While up to half of people with lupus develop lupus nephritis, a new survey by the Lupus […] Read More

LRA Pleased to Share GSK’s Benlysta® (belimumab) is First Lupus Nephritis Treatment Approved by FDA

NEW YORK, NY. December 17, 2020. The Lupus Research Alliance (LRA) congratulates GSK on the U.S. Food and Drug Administration (FDA) approval of belimumab (Benlysta®) as the first-ever treatment specifically indicated for lupus nephritis (LN) in adults. Another milestone, this new indication is the only FDA approval of a new lupus treatment since belimumab was […] Read More

LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis

September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug Benlysta® (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney. The […] Read More

The Lupus Research Alliance Partners with the National Kidney Foundation to Offer Course to Healthcare Professionals

November 12, 2019 The Lupus Research Alliance (LRA) is pleased to announce a new collaboration with the National Kidney Foundation (NKF) on a free course for healthcare professionals about ways to better diagnose, monitor and treat patients with systemic lupus erythematosus (SLE) and lupus nephritis. The online course is critically important because as the community […] Read More

Lupus Research Alliance Response to Positive Trial Testing Obinutuzumab (Gazyva®) for Lupus Nephritis

NEW YORK, Nov. 10, 2019 /PRNewswire/ — The Lupus Research Alliance (LRA) is pleased to acknowledge positive results presented by Genentech at the American Society of Nephrology (ASN) and the 2019 ACR/ARP Annual Meeting showing the effectiveness of obinutuzumab (Gazyva®), a type I anti-CD20 monoclonal antibody, in the Phase 2 NOBILITY trial for the most severe […] Read More